Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, once-daily, oral therapies to lower levels of low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Jan 20, 2017
Last Price 11.08 Change -0.05(-0.449%) open 11.14 Day High 11.21 52-Week High 20.19
Volume 91,994 Previous Close 11.13 Day Low 10.91 52-Week Low 9.40

Press Releases

Load More